FindTrial
Sign In

Phase 2 Study to Evaluate Safety and Pharmacodynamics of CS-3150 in Type 2 Diabetes Mellitus Patients with Albuminuria

Phase 2 Study to Evaluate Safety and Pharmacodynamics of CS-3150 in Type 2 Diabetes Mellitus Patients with Albuminuria

Status
Unknown
Phases
Phase 2
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080221972
Enrollment
Unknown
Registered
2012-12-04
Start date
2012-12-04
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Diabetes Mellitus

Interventions

investigational material(s) Generic name etc : CS-3150 INN of investigational material : Therapeutic category code : 214 Antihypertensives Dosage and Administration for Investigational material : Ora

Sponsors

DAIICHISANKYO Co.,Ltd.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Main Inclusion Criteria; -A diagnosis of Type 2 Diabetes Mellitus with Albuminuria -Male and Female of 30 to 70 years of age -Complication of Hypertension

Exclusion criteria

Exclusion criteria: Main Exclusion Criteria; -Type 1 Diabetes Mellitus -Patients with known Non-Diabetic Renal Disease

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026